Benvitimod

ApprovedSmall molecule

PPeking University People's Hospital

Benvitimod is one of 101 small molecule programs targeting Cutaneous T-cell lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous T-Cell LymphomaNot yet recruiting

PsoriasisActive, not recruiting

Atopic DermatitisActive, not recruiting

Cutaneous T-Cell LymphomaPhase 2

Not yet recruiting

PsoriasisApproved

Active, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Benvitimod

PPeking University People's Hospital

Approved

2 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Raptiva

Roche

Preclinical

10 8

Remicade

OOrganon and Co

Preclinical

20 9

Siliq

BBausch Health Americas, Inc.

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Cutaneous T-Cell Lymphoma

NCT07658924

Clinical

Trials by Indication[1]

Psoriasis2 trials

Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults

Unknown status·PPeking University People's Hospital·Phase 4·NCT05064748·2,000 enrolled

Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis

Unknown status·PPeking University People's Hospital·N/A·NCT05326659·390 enrolled

Atopic Dermatitis1 trial

Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis

Unknown status·PPeking University People's Hospital·Phase 3·NCT05326672·240 enrolled

Cutaneous T-cell lymphoma1 trial

Evaluation of the Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma

Not yet recruiting·PPeking University First Hospital·Phase 2·NCT07658924·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Benvitimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Benvitimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Benvitimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPeking University People's Hospital

Benvitimod

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Psoriasis2 trials

Atopic Dermatitis1 trial

Cutaneous T-cell lymphoma1 trial

References

Drug Info

Quick Facts

Related News